Association of Cyp2c9 gene polymorphism with bleeding as a complication of warfarin therapy

Collegium Antropologicum

Volumn 32, Issue 2, 2008, Pages 557-564

  Samardžija, Marina ^a   Topić, Elizabeta ^b   Štefanović, Mario ^b   Zibar, Lada ^a   Samardžija, Goran ^a   Balen, Sanja ^c   Včev, Aleksandar ^a   Domanović, Dragoslav ^d   Mirat, Jure ^e   Barbić, Jerko ^a  

^a UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c KBC RIJEKA   (Croatia)

^d BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

^e University Hospital Sveti Duh   (Croatia)

Author keywords

Bleeding; CYP2C9; Gene polymorphism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P 450 CYP2C SUBFAMILY; CYTOCHROME P-450 CYP2C SUBFAMILY; CYTOCHROME P450; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD; CHEMICALLY INDUCED DISORDER; CHILD; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; PROTHROMBIN TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTHROMBIN TIME; WARFARIN;

EID: 52649159919     PISSN: 03506134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. TOPIĆ E, Laboratorijsko istraživanje bolesti jetre (Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, 2001).
2. ŠERMAN D, STAVLJENIĆ-RUKAVINA A, SERTIĆ J, BULIĆ-JAKUŠ F, Metode molekularne biologije u medicini (Medicinska naklada, Zagreb, 2001).
3. MEYER UA, Lancet, 356 (2000) 1667.
4. WOLF RC, SMITH G, SMITH RL, BMJ, 320 (2000) 987.
5. MEYER UA, Annu Rev Pharmacol Toxicol, 37 (1997) 269.
6. EVANS, WE, RELLING MV, Science, 286 (1999) 487.
7. INGELMAN-SUNDBERG M, OSCARSON M, McLELLAN RA, Trends Pharmacol Sci, 20 (1999) 342.
8. LINDER MW, PROUGH RA, VALDES RJR, Clin Chem, 43 (1997) 254.
9. BARBARA MA, Blood Components and Pharmacologic Agents in the Treatment of Congenital and Acquired Bleeding Disorders (AABB Press, Bethesda, 2000).
10. HIRSH J, DALEN JE, ANDERSON DR, POLLER L, BUSSEY H, ANSELL J, Chest, 114 (1998) 445.
11. VRHOVAC B, Interna medicina (Naprijed, Zagreb, 1997).
12. BULAT M, GEBER J, LACKOVIĆ Z, Medicinska farmakologija (Medicinska naklada, Zagreb, 1999).
13. FONNE-PFISTER R, MEYER UA, Biochem Pharmacol, 37 (1988) 3829.
14. VRHOVAC B, REINER Ž, Farmakoterapijski priručnik (Med-Ekon, Zagreb, 2000).
15. HARRISON TR, Principles of Internal Medicine. (McGraw-Hill, 1994).
16. IYER L, RATAIN MJ, Eur J Cancer, 34 (1998) 1493.
17. WILLIAMS PA, OSME J, WARD A, ANGOVE HC, MATAK VINKOVIC D, Nature, 424 (2003) 464.
18. GONZALES FJ, NEBERT DW, TIG, 6 (1990) 182.
19. LEE CR, GOLDSTEIN JA, PIEPER JA, Pharmacogenetics, 12 (2002) 251.
20. HIGASHI MK, VEENSTRA DL, KONDO LM, WITTKOVSKY AK, SRINOUANPRACHANH SL, FARIN FM, RETTIE AE, JAMA, 287 (2002) 1690.
21. AITHAL GP, DAY CP, KESTEVEN PJL, DALY AK, Lancet, 353 (1999) 717.
22. TAUBE J, HALSALL D, BAGLIN T, Blood, 96 (2000) 1816.
23. SCORDO MG, PENGO V, SPINA E, DAHL ML, GUSELLA M, PADRINI R, Clin Pharmacol Ther, 72 (2002) 702.
24. WITTKOWSKY AK, J Thromb Thrombolysis, 12 (2001) 67.
25. FREEMAN BD, ZEHNBAUER BA, McGRATH S, BORECKI I, BUCHMAN TG, Surgery, 128 (2000) 281.
26. HAINING RL, HUNTER AP, VERONESE ME, TRAGER WF, RETTIE AE, Arch Biochem Biophys, 333 (1996) 447.
27. TAKAHASHI H, ECHIZEN H, Clin Pharmacokinet, 40 (2001) 587.
28. OGGS MS, BRENNAN P, MEADE T, HUMPHRIES SE, Lancet, 354 (1999) 1124.
29. WADELIUS M, SORLIN K, WALLRMAN O, KARLSSON J, YUE QY, MAGNUSSO PK, WADELIUS C, MELHUS H, Pharmacogenomics J, 4 (2004) 40.
30. MARGAGLIONE M, COLAIZZO D, D'ANDREA G, BRANACACCIO V, CIAMPA A, GRANDONE E, Thromb Haemost, 84 (2000) 775.